1. |
|
|
2. |
|
|
3. |
|
|
4. |
- Ridderstråle, Martin, et al.
(author)
-
Fallbeskrivning. Rosiglitazonbehandling gav kraftfull effekt, men fick ändå avbrytas
- 2002
-
In: Läkartidningen. - 0023-7205. ; 99:5, s. 407-410
-
Journal article (peer-reviewed)abstract
- The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.
|
|